{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:56:23Z","timestamp":1790650583819,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Hubei Province's Outstanding Medical Academic Leader program"},{"name":"joint supported by Hubei Provincial Natural Science Foundation and Shiyan of China","award":["2025AFD174"],"award-info":[{"award-number":["2025AFD174"]}]},{"name":"DBT-funded Bioinformatics Infrastructure Facility Centre","award":["BT\/PR40162\/BTIS\/137\/48\/2022, dated 31.10.2022"],"award-info":[{"award-number":["BT\/PR40162\/BTIS\/137\/48\/2022, dated 31.10.2022"]}]},{"name":"National Network Project","award":["BT\/PR40192\/BTIS\/137\/69\/2023, dated 19.12.2023"],"award-info":[{"award-number":["BT\/PR40192\/BTIS\/137\/69\/2023, dated 19.12.2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer remains a major global health burden and is characterized by substantial molecular and clinical heterogeneity. In recent years, considerable progress has been made in elucidating the genetic and molecular mechanisms underlying breast cancer, particularly those associated with hereditary susceptibility. Advances in genomic and functional studies have further revealed the complex mutational landscape of breast cancer, including key alterations in tumor suppressor genes, oncogenic signaling pathways, and mutagenic processes. In addition, non-coding RNAs (ncRNAs) have emerged as important regulators of gene expression, influencing tumor progression and therapeutic resistance. Emerging strategies, including immunotherapy, precision medicine, and nanoparticle-based drug delivery systems, have significantly expanded treatment options and improved clinical outcomes. However, challenges such as tumor heterogeneity, drug resistance, systemic toxicity, and disparities in healthcare access continue to limit the effectiveness and broad implementation of these therapies. This review provides a comprehensive overview of the molecular mechanisms of breast cancer from a hereditary perspective, with a particular focus on genetic susceptibility, ncRNAs, and emerging therapeutic strategies. Additionally, it highlights current limitations and future directions, emphasizing the need for integrative approaches that combine genomic insights, advanced technologies, and personalized medicine to improve breast cancer prevention and treatment.<\/jats:p>","DOI":"10.1186\/s41065-026-00720-8","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:01:41Z","timestamp":1790550101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary breast cancer: emerging roles of non-coding RNAs"],"prefix":"10.1186","volume":"163","author":[{"given":"Zhenshan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanjan","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglu","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshuman","family":"Bagchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"720_CR1","unstructured":"Breast cancer: World Health Organization. 2026. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. [updated 2026-04-16; Cited 2026 05\u201316]."},{"key":"720_CR2","doi-asserted-by":"publisher","unstructured":"Carvalho E, Canberk S, Schmitt F, Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025;17(7):1102. https:\/\/doi.org\/10.3390\/cancers17071102.","DOI":"10.3390\/cancers17071102"},{"issue":"1","key":"720_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ogc.2021.11.010","volume":"49","author":"VF Grabinski","year":"2022","unstructured":"Grabinski VF, Brawley OW. Disparities in Breast Cancer. Obstet Gynecol Clin N Am. 2022;49(1):149\u201365.","journal-title":"Obstet Gynecol Clin N Am"},{"issue":"2","key":"720_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3322\/caac.21874","volume":"75","author":"AH Saka","year":"2025","unstructured":"Saka AH, Giaquinto AN, McCullough LE, Tossas KY, Star J, Jemal A, et al. Cancer statistics for African American and Black people, 2025. Cancer J Clin. 2025;75(2):111\u201340.","journal-title":"Cancer J Clin"},{"issue":"6","key":"720_CR5","first-page":"565","volume":"35","author":"H Xu","year":"2023","unstructured":"Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chin J cancer Res = Chung-kuo yen cheng yen chiu. 2023;35(6):565\u201383.","journal-title":"Chin J cancer Res = Chung-kuo yen cheng yen chiu"},{"issue":"1","key":"720_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12282-008-0077-5","volume":"16","author":"T Morimoto","year":"2009","unstructured":"Morimoto T, Nagao T, Okazaki K, Kira M, Nakagawa Y, Tangoku A. Current status of breast cancer screening in the world. Breast cancer (Tokyo Japan). 2009;16(1):2\u20139.","journal-title":"Breast cancer (Tokyo Japan)"},{"issue":"1","key":"720_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4314\/gmj.v51i1.2","volume":"51","author":"OA Omidiji","year":"2017","unstructured":"Omidiji OA, Campbell PC, Irurhe NK, Atalabi OM, Toyobo OO. Breast cancer screening in a resource poor country: Ultrasound versus mammography. Ghana Med J. 2017;51(1):6\u201312.","journal-title":"Ghana Med J"},{"issue":"1","key":"720_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","volume":"3","author":"KS Johnson","year":"2021","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. J breast imaging. 2021;3(1):12\u201324.","journal-title":"J breast imaging"},{"issue":"4","key":"720_CR9","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/cam4.2012","volume":"8","author":"L Zhang","year":"2019","unstructured":"Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, et al. Comparison of breast cancer risk factors among molecular subtypes: A case-only study. Cancer Med. 2019;8(4):1882\u201392.","journal-title":"Cancer Med"},{"issue":"1","key":"720_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12609-026-00636-2","volume":"18","author":"L Jahangiri","year":"2026","unstructured":"Jahangiri L. Genetic Aspects of Breast Cancer: an Update. Curr Breast Cancer Rep. 2026;18(1):11.","journal-title":"Curr Breast Cancer Rep"},{"issue":"5","key":"720_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"720_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41431-025-02003-8","volume":"34","author":"HM Tanha","year":"2026","unstructured":"Tanha HM, Law MH, Ingold N, Olsen CM, Pandeya N, Milne RL, et al. Performance of different polygenic risk scores for breast cancer risk prediction: in-depth evaluations across large UK and Australian cohorts. Eur J Hum genetics: EJHG. 2026;34(2):278\u201387.","journal-title":"Eur J Hum genetics: EJHG"},{"key":"720_CR13","unstructured":"Hereditary Cancer Awareness Week. Available from: https:\/\/ovarian.org.uk\/get-involved\/campaigns\/hereditary-cancer-awareness-week\/.\u00a0[cited 2026 05-16]."},{"key":"720_CR14","doi-asserted-by":"publisher","unstructured":"Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1):10.15761\/ICST.1000228. https:\/\/doi.org\/10.15761\/ICST.1000228.","DOI":"10.15761\/ICST.1000228"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/PGPM.S233485","volume":"13","author":"S Peleg Hasson","year":"2020","unstructured":"Peleg Hasson S, Menes T, Sonnenblick A. Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes. Pharmacogenomics personalized Med. 2020;13:227\u201338.","journal-title":"Pharmacogenomics personalized Med"},{"issue":"5","key":"720_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C, Wahlstr\u00f6m C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"720_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12957-024-03553-9","volume":"22","author":"M Pal","year":"2024","unstructured":"Pal M, Das D, Pandey M. Understanding genetic variations associated with familial breast cancer. World J Surg Oncol. 2024;22(1):271.","journal-title":"World J Surg Oncol"},{"key":"720_CR18","doi-asserted-by":"publisher","unstructured":"Fan X, Wynn J, Shang N, Liu C, Fedotov A, Hallquist MLG, et al. Penetrance of breast cancer susceptibility genes from the eMERGE III network. JNCI Cancer Spectr. 2021;5(4):pkab044. https:\/\/doi.org\/10.1093\/jncics\/pkab044.","DOI":"10.1093\/jncics\/pkab044"},{"issue":"6","key":"720_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylk\u00e4s K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497\u2013506.","journal-title":"N Engl J Med"},{"issue":"4","key":"720_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1158\/0008-5472.CAN-21-1845","volume":"82","author":"R Boonen","year":"2022","unstructured":"Boonen R, Wiegant WW, Celosse N, Vroling B, Heijl S, Kote-Jarai Z, et al. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk. Cancer Res. 2022;82(4):615\u201331.","journal-title":"Cancer Res"},{"issue":"5","key":"720_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ijrobp.2021.01.045","volume":"110","author":"SGR McDuff","year":"2021","unstructured":"McDuff SGR, Bellon JR, Shannon KM, Gadd MA, Dunn S, Rosenstein BS, et al. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations. Int J Radiat Oncol Biol Phys. 2021;110(5):1373\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"720_CR22","first-page":"145","volume":"4","author":"P Rizzolo","year":"2011","unstructured":"Rizzolo P, Silvestri V, Falchetti M, Ottini L. Inherited and acquired alterations in development of breast cancer. application Clin Genet. 2011;4:145\u201358.","journal-title":"application Clin Genet"},{"issue":"1","key":"720_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target therapy. 2025;10(1):49.","journal-title":"Signal Transduct Target therapy"},{"issue":"2","key":"720_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2024.11.009","volume":"188","author":"W Mei","year":"2025","unstructured":"Mei W, Faraj Tabrizi S, Godina C, Lovisa AF, Isaksson K, Jernstr\u00f6m H, et al. A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. Cell. 2025;188(2):371\u2013e8928.","journal-title":"Cell"},{"issue":"12","key":"720_CR25","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1038\/s41588-024-01958-6","volume":"56","author":"CM Li","year":"2024","unstructured":"Li CM, Cordes A, Oliphant MUJ, Quinn SA, Thomas M, Selfors LM, et al. Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer. Nat Genet. 2024;56(12):2763\u201375.","journal-title":"Nat Genet"},{"issue":"9","key":"720_CR26","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41588-025-02322-y","volume":"57","author":"S Yao","year":"2025","unstructured":"Yao S, Wei L, Hu Q, Liu S, Manojlovic Z, Fiorica PN, et al. Mutational landscape of triple-negative breast cancer in African American women. Nat Genet. 2025;57(9):2166\u201376.","journal-title":"Nat Genet"},{"issue":"1","key":"720_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41588-024-02031-y","volume":"57","author":"G Jia","year":"2025","unstructured":"Jia G, Chen Z, Ping J, Cai Q, Tao R, Li C, et al. Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions. Nat Genet. 2025;57(1):80\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"720_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jnci\/djae208","volume":"117","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Lindstr\u00f6m S, Kraft P, Liu Y. Genetic risk, health-associated lifestyle, and risk of early-onset total cancer and breast cancer. J Natl Cancer Inst. 2025;117(1):40\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"720_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.breast.2023.01.003","volume":"67","author":"E Roberts","year":"2023","unstructured":"Roberts E, Howell S, Evans DG. Polygenic risk scores and breast cancer risk prediction. Breast (Edinburgh Scotland). 2023;67:71\u20137.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"1","key":"720_CR30","doi-asserted-by":"publisher","first-page":"114375","DOI":"10.1016\/j.isci.2025.114375","volume":"29","author":"HHK Nguyen","year":"2026","unstructured":"Nguyen HHK, Le HM, Le TQ, Dinh NTQ, Nguyen TT, Nguyen PA, et al. Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements. iScience. 2026;29(1):114375.","journal-title":"iScience"},{"issue":"1","key":"720_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104(1):21\u201334.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"720_CR32","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1038\/s41467-020-17680-w","volume":"11","author":"WK Ho","year":"2020","unstructured":"Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, et al. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun. 2020;11(1):3833.","journal-title":"Nat Commun"},{"key":"720_CR33","doi-asserted-by":"publisher","unstructured":"Garcia-Closas M, Gunsoy NB, Chatterjee N. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst. 2014;106(11):dju305. https:\/\/doi.org\/10.1093\/jnci\/dju305.","DOI":"10.1093\/jnci\/dju305"},{"key":"720_CR34","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.drup.2025.101288","volume":"83","author":"GY Wu","year":"2025","unstructured":"Wu GY, Xiao MZ, Hao WC, Yang ZS, Liu XR, Xu DS, et al. Drug resistance in breast cancer: Mechanisms and strategies for management. Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother. 2025;83:101288.","journal-title":"Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother"},{"issue":"6","key":"720_CR35","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","volume":"57","author":"A Gupta","year":"2025","unstructured":"Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Nat Genet. 2025;57(6):1452\u201362.","journal-title":"Nat Genet"},{"issue":"8","key":"720_CR36","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708\u201328.","journal-title":"Cell"},{"issue":"10","key":"720_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Cancer Network: JNCCN. 2023;21(10):1000\u201310.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"5","key":"720_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin oncology: official J Am Soc Clin Oncol. 2024;42(5):584\u2013604.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"720_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Annals oncology: official J Eur Soc Med Oncol. 2023;34(1):33\u201347.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"720_CR40","doi-asserted-by":"publisher","first-page":"1497510","DOI":"10.3389\/fsysb.2024.1497510","volume":"4","author":"D Guha","year":"2024","unstructured":"Guha D, Mondal J, Nandy A, Biswas S, Bagchi A. Interplay of circular RNAs in gastric cancer - a systematic review. Front Syst biology. 2024;4:1497510.","journal-title":"Front Syst biology"},{"key":"720_CR41","doi-asserted-by":"publisher","unstructured":"Be\u0148a\u010dka R, Szab\u00f3ov\u00e1 D, Gu\u013ea\u0161ov\u00e1 Z, Hertelyov\u00e1 Z, Rado\u0148ak J. Non-coding RNAs in human cancer and other diseases: overview of the diagnostic potential. Int J Mol Sci. 2023;24(22):16213. https:\/\/doi.org\/10.3390\/ijms242216213.","DOI":"10.3390\/ijms242216213"},{"issue":"3","key":"720_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ijc.29021","volume":"136","author":"M Tanic","year":"2015","unstructured":"Tanic M, Yanowski K, G\u00f3mez-L\u00f3pez G, Rodriguez-Pinilla MS, Marquez-Rodas I, Osorio A, et al. MicroRNA expression signatures for the prediction of BRCA1\/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors. Int J Cancer. 2015;136(3):593\u2013602.","journal-title":"Int J Cancer"},{"issue":"1","key":"720_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10549-013-2723-7","volume":"142","author":"R Murria Estal","year":"2013","unstructured":"Murria Estal R, Palanca Suela S, de Juan Jim\u00e9nez I, Egoavil Rojas C, Garc\u00eda-Casado Z, Juan Fita MJ, et al. MicroRNA signatures in hereditary breast cancer. Breast Cancer Res Treat. 2013;142(1):19\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"720_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/1566524013666131203101405","volume":"14","author":"R Pinto","year":"2014","unstructured":"Pinto R, De Summa S, Pilato B, Tommasi S. DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer. Curr Mol Med. 2014;14(1):45\u201357.","journal-title":"Curr Mol Med"},{"issue":"6","key":"720_CR45","doi-asserted-by":"publisher","first-page":"e38847","DOI":"10.1371\/journal.pone.0038847","volume":"7","author":"M Tanic","year":"2012","unstructured":"Tanic M, Yanowsky K, Rodriguez-Antona C, Andr\u00e9s R, M\u00e1rquez-Rodas I, Osorio A, et al. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS ONE. 2012;7(6):e38847.","journal-title":"PLoS ONE"},{"key":"720_CR46","doi-asserted-by":"publisher","unstructured":"Landeros N, Gonzalez-Hormazabal P, P\u00e9rez-Moreno P, Tapia JC, Jara L. A single variant in pri-miRNA-155 associated with susceptibility to hereditary breast cancer promotes aggressiveness in breast cancer cells. Int J Mol Sci. 2022;23(23):15418. https:\/\/doi.org\/10.3390\/ijms232315418.","DOI":"10.3390\/ijms232315418"},{"key":"720_CR47","doi-asserted-by":"publisher","unstructured":"Cantile M, Di Bonito M, Cerrone M, Collina F, De Laurentiis M, Botti G. Long non-coding RNA HOTAIR in breast cancer therapy. Cancers. 2020;12(5):1197. https:\/\/doi.org\/10.3390\/cancers12051197.","DOI":"10.3390\/cancers12051197"},{"issue":"6 Suppl 2","key":"720_CR48","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/j.bj.2020.11.002","volume":"44","author":"X Yue","year":"2021","unstructured":"Yue X, Wu WY, Dong M, Guo M. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p. Biomedical J. 2021;44(6 Suppl 2):S296\u2013304.","journal-title":"Biomedical J"},{"key":"720_CR49","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhang Y, Hu K, Qiu J, Hu Y, Zhou M, et al. Elevated long noncoding RNA MALAT-1 expression is predictive of poor prognosis in patients with breast cancer: a meta-analysis. Biosci Rep. 2020;40(8):BSR20200215. https:\/\/doi.org\/10.1042\/BSR20200215.","DOI":"10.1042\/BSR20200215"},{"issue":"34","key":"720_CR50","doi-asserted-by":"publisher","first-page":"24731","DOI":"10.1074\/jbc.M702029200","volume":"282","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007;282(34):24731\u201342.","journal-title":"J Biol Chem"},{"issue":"24","key":"720_CR51","first-page":"5143","volume":"20","author":"JJ Zhang","year":"2016","unstructured":"Zhang JJ, Guo SH, Jia BQ. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer. Eur Rev Med Pharmacol Sci. 2016;20(24):5143\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"720_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41419-019-1513-5","volume":"10","author":"VY Shin","year":"2019","unstructured":"Shin VY, Chen J, Cheuk IW, Siu MT, Ho CW, Wang X, et al. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019;10(4):270.","journal-title":"Cell Death Dis"},{"key":"720_CR53","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.2147\/CMAR.S252295","volume":"12","author":"S Li","year":"2020","unstructured":"Li S, Hao J, Hong Y, Mai J, Huang W. Long Non-Coding RNA NEAT1 Promotes the Proliferation, Migration, and Metastasis of Human Breast-Cancer Cells by Inhibiting miR-146b-5p Expression. Cancer Manage Res. 2020;12:6091\u2013101.","journal-title":"Cancer Manage Res"},{"issue":"3","key":"720_CR54","first-page":"953","volume":"9","author":"H Fang","year":"2017","unstructured":"Fang H, Xie J, Zhang M, Zhao Z, Wan Y, Yao Y. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J translational Res. 2017;9(3):953\u201361.","journal-title":"Am J translational Res"},{"issue":"3","key":"720_CR55","first-page":"225","volume":"16","author":"J Chen","year":"2014","unstructured":"Chen J, Wang X. MicroRNA-21 in breast cancer: diagnostic and prognostic potential. Clinical & translational oncology: official. publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2014;16(3):225\u201333.","journal-title":"publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"720_CR56","doi-asserted-by":"publisher","unstructured":"Wang J, Wang Q, Guan Y, Sun Y, Wang X, Lively K, et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Investig. 2022;132(19):e157248. https:\/\/doi.org\/10.1172\/JCI157248.","DOI":"10.1172\/JCI157248"},{"issue":"1","key":"720_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-023-07170-0","volume":"204","author":"SMM Yahya","year":"2024","unstructured":"Yahya SMM, Nabih HK, Elsayed GH, Mohamed SIA, Elfiky AM, Salem SM. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. Breast Cancer Res Treat. 2024;204(1):133\u201349.","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"720_CR58","doi-asserted-by":"publisher","first-page":"14910","DOI":"10.1074\/jbc.C800074200","volume":"283","author":"M Korpal","year":"2008","unstructured":"Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283(22):14910\u20134.","journal-title":"J Biol Chem"},{"key":"720_CR59","doi-asserted-by":"publisher","first-page":"102097","DOI":"10.1016\/j.canep.2022.102097","volume":"77","author":"T Thi Chung Duong","year":"2022","unstructured":"Thi Chung Duong T, Nguyen THN, Thi Ngoc Nguyen T, Huynh LH, Ngo HP, Thi Nguyen H. Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review. Cancer Epidemiol. 2022;77:102097.","journal-title":"Cancer Epidemiol"},{"key":"720_CR60","doi-asserted-by":"publisher","first-page":"11215","DOI":"10.1038\/ncomms11215","volume":"7","author":"Q Zheng","year":"2016","unstructured":"Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.","journal-title":"Nat Commun"},{"key":"720_CR61","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1016\/j.plabm.2025.e00470","volume":"45","author":"E Bahadoran","year":"2025","unstructured":"Bahadoran E, Mohammadi D, Jalilvand M, Moghbelinejad S. Evaluation of CircHIPK3 biomarker potential in breast cancer. Practical Lab Med. 2025;45:e00470.","journal-title":"Practical Lab Med"},{"issue":"8","key":"720_CR62","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1111\/jcmm.14305","volume":"23","author":"W Yang","year":"2019","unstructured":"Yang W, Yang X, Wang X, Gu J, Zhou D, Wang Y, et al. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REG\u03b3. J Cell Mol Med. 2019;23(8):4921\u201332.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"720_CR63","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s40001-024-02015-y","volume":"29","author":"C Yuan","year":"2024","unstructured":"Yuan C, Xu Y, Zhou L, Peng J, Sha R, Lin Y, et al. Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort. Eur J Med Res. 2024;29(1):454.","journal-title":"Eur J Med Res"},{"issue":"7","key":"720_CR64","first-page":"1566","volume":"7","author":"HF Liang","year":"2017","unstructured":"Liang HF, Zhang XZ, Liu BG, Jia GT, Li WL. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J cancer Res. 2017;7(7):1566\u201376.","journal-title":"Am J cancer Res"},{"issue":"12","key":"720_CR65","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.3390\/cimb46120862","volume":"46","author":"B \u0130lhan","year":"2024","unstructured":"\u0130lhan B, Ender \u015e, K\u0131l\u0131\u00e7 B, \u00dc\u00e7\u00fcnc\u00fc M, Serilmez M, Tilgen Yasasever C, et al. The Diagnostic Value of circFBXW7, circABCB10, and circ0103552 Levels in Breast Cancer. Curr Issues Mol Biol. 2024;46(12):14381\u201393.","journal-title":"Curr Issues Mol Biol"},{"key":"720_CR66","doi-asserted-by":"publisher","first-page":"111079","DOI":"10.1016\/j.cellsig.2024.111079","volume":"117","author":"D Chen","year":"2024","unstructured":"Chen D, Zeng S, Qiu H, Yang M, Lin X, Lv X, et al. Circ-FOXO3 inhibits triple-negative breast cancer growth and metastasis via regulating WHSC1-H3K36me2-Zeb2 axis. Cell Signal. 2024;117:111079.","journal-title":"Cell Signal"},{"issue":"1","key":"720_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15257770.2024.2437037","volume":"45","author":"\u00c7 \u00d6ner","year":"2026","unstructured":"\u00d6ner \u00c7, K\u00f6ser F, \u00c7olak E. The association of piR-651 and piR-823 on metastatic and invasive characteristics of triple negative breast cancer cells. Nucleosides Nucleotides Nucleic Acids. 2026;45(1):1\u201317.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"16","key":"720_CR68","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1080\/15384101.2021.1956090","volume":"20","author":"T Liu","year":"2021","unstructured":"Liu T, Wang J, Sun L, Li M, He X, Jiang J, et al. Piwi-interacting RNA-651 promotes cell proliferation and migration and inhibits apoptosis in breast cancer by facilitating DNMT1-mediated PTEN promoter methylation. Cell cycle (Georgetown Tex). 2021;20(16):1603\u201316.","journal-title":"Cell cycle (Georgetown Tex)"},{"key":"720_CR69","doi-asserted-by":"publisher","first-page":"641052","DOI":"10.3389\/fcell.2021.641052","volume":"9","author":"X Ding","year":"2021","unstructured":"Ding X, Li Y, L\u00fc J, Zhao Q, Guo Y, Lu Z, et al. piRNA-823 Is Involved in Cancer Stem Cell Regulation Through Altering DNA Methylation in Association With Luminal Breast Cancer. Front cell Dev biology. 2021;9:641052.","journal-title":"Front cell Dev biology"},{"issue":"1","key":"720_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-019-0940-3","volume":"18","author":"L Tan","year":"2019","unstructured":"Tan L, Mai D, Zhang B, Jiang X, Zhang J, Bai R, et al. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019;18(1):9.","journal-title":"Mol Cancer"},{"key":"720_CR71","doi-asserted-by":"publisher","unstructured":"Nadhan R, Isidoro C, Song YS, Dhanasekaran DN. Signaling by LncRNAs: structure, cellular homeostasis, and disease pathology. Cells. 2022;11(16):2517. https:\/\/doi.org\/10.3390\/cells11162517.","DOI":"10.3390\/cells11162517"},{"issue":"1","key":"720_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12935-025-03679-0","volume":"25","author":"M Solaimani","year":"2025","unstructured":"Solaimani M, Hosseinzadeh S, Abasi M. Non-coding RNAs, a double-edged sword in breast cancer prognosis. Cancer Cell Int. 2025;25(1):123.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"720_CR73","first-page":"885","volume":"46","author":"R Bhattacharjee","year":"2023","unstructured":"Bhattacharjee R, Prabhakar N, Kumar L, Bhattacharjee A, Kar S, Malik S, et al. Crosstalk between long noncoding RNA and microRNA in Cancer. Cell Oncol (Dordrecht Netherlands). 2023;46(4):885\u2013908.","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"720_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gene.2018.03.011","volume":"658","author":"B Xiao","year":"2018","unstructured":"Xiao B, Zhang W, Chen L, Hang J, Wang L, Zhang R, et al. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. Gene. 2018;658:28\u201335.","journal-title":"Gene"},{"key":"720_CR75","doi-asserted-by":"publisher","unstructured":"Shinde SS, Ahmed S, Malik JA, Hani U, Khanam A, Ashraf Bhat F, et al. Therapeutic delivery of tumor suppressor miRNAs for breast cancer treatment. Biology. 2023;12(3):467. https:\/\/doi.org\/10.3390\/biology12030467.","DOI":"10.3390\/biology12030467"},{"key":"720_CR76","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol. 2018;9:402.","journal-title":"Front Endocrinol"},{"issue":"2","key":"720_CR77","first-page":"201","volume":"34","author":"BP Chang","year":"2014","unstructured":"Chang BP, Wang DS, Xing JW, Yang SH, Chu Q, Yu SY. miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. Journal of Huazhong University of Science and Technology Medical sciences\u2009=\u2009Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban\u2009=\u2009Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2014;34(2):201\u20136.","journal-title":"Yixue Yingdewen ban"},{"issue":"1","key":"720_CR78","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncrna.2016.10.003","volume":"1","author":"CK Thammaiah","year":"2016","unstructured":"Thammaiah CK, Jayaram S. Role of let-7 family microRNA in breast cancer. Non-coding RNA Res. 2016;1(1):77\u201382.","journal-title":"Non-coding RNA Res"},{"issue":"10","key":"720_CR79","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/0008-5472.CAN-10-2435","volume":"71","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71(10):3552\u201362.","journal-title":"Cancer Res"},{"issue":"12","key":"720_CR80","doi-asserted-by":"publisher","first-page":"22285","DOI":"10.1002\/jcp.28795","volume":"234","author":"S Hossainzadeh","year":"2019","unstructured":"Hossainzadeh S, Ranji N, Naderi Sohi A, Najafi F. Silibinin encapsulation in polymersome: A promising anticancer nanoparticle for inducing apoptosis and decreasing the expression level of miR-125b\/miR-182 in human breast cancer cells. J Cell Physiol. 2019;234(12):22285\u201398.","journal-title":"J Cell Physiol"},{"issue":"1","key":"720_CR81","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-017-0663-2","volume":"16","author":"S Meng","year":"2017","unstructured":"Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017;16(1):94.","journal-title":"Mol Cancer"},{"issue":"1","key":"720_CR82","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12943-024-02131-7","volume":"23","author":"Q Yi","year":"2024","unstructured":"Yi Q, Feng J, Lan W, Shi H, Sun W, Sun W. CircRNA and lncRNA-encoded peptide in diseases, an update review. Mol Cancer. 2024;23(1):214.","journal-title":"Mol Cancer"},{"issue":"2","key":"720_CR83","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/cdd.2016.133","volume":"24","author":"WW Du","year":"2017","unstructured":"Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017;24(2):357\u201370.","journal-title":"Cell Death Differ"},{"key":"720_CR84","doi-asserted-by":"publisher","first-page":"1775335","DOI":"10.3389\/fmolb.2026.1775335","volume":"13","author":"Q Yang","year":"2026","unstructured":"Yang Q, Wu J, Su Y. Emerging roles of PIWI-interacting RNAs in cancer molecular diagnostics and therapeutics: a molecular biosciences perspective. Front Mol Biosci. 2026;13:1775335.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"720_CR85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12964-023-01368-x","volume":"21","author":"Z Wu","year":"2023","unstructured":"Wu Z, Yu X, Zhang S, He Y, Guo W. Novel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases. Cell communication signaling: CCS. 2023;21(1):343.","journal-title":"Cell communication signaling: CCS"},{"key":"720_CR86","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.aspetd.2025.100012","volume":"1","author":"JV Eapen","year":"2025","unstructured":"Eapen JV, George P, Thomas S, Antony J. Integrative strategies in breast cancer therapy: Conventional approaches, emerging advances, and future challenges. ASPET Discovery. 2025;1:100012.","journal-title":"ASPET Discovery"},{"issue":"4","key":"720_CR87","first-page":"1045","volume":"10","author":"J Kreutzfeldt","year":"2020","unstructured":"Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2\u2009+\u2009breast cancer therapies. Am J cancer Res. 2020;10(4):1045\u201367.","journal-title":"Am J cancer Res"},{"issue":"7","key":"720_CR88","first-page":"2920","volume":"12","author":"M Tufail","year":"2022","unstructured":"Tufail M, Cui J, Wu C. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Am J cancer Res. 2022;12(7):2920\u201349.","journal-title":"Am J cancer Res"},{"key":"720_CR89","doi-asserted-by":"publisher","first-page":"1452666","DOI":"10.3389\/fonc.2024.1452666","volume":"14","author":"R Li","year":"2024","unstructured":"Li R, Ji Y, Ye R, Tang G, Wang W, Chen C, et al. Potential therapies for non-coding RNAs in breast cancer. Front Oncol. 2024;14:1452666.","journal-title":"Front Oncol"},{"key":"720_CR90","doi-asserted-by":"publisher","unstructured":"Be\u0148a\u010dka R, Szab\u00f3ov\u00e1 D, Gu\u013ea\u0161ov\u00e1 Z, Hertelyov\u00e1 Z. Non-coding RNAs in breast cancer: diagnostic and therapeutic implications. Int J Mol Sci. 2024;26(1):127. https:\/\/doi.org\/10.3390\/ijms26010127.","DOI":"10.3390\/ijms26010127"},{"key":"720_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms231911502","volume":"23","author":"A Menon","year":"2022","unstructured":"Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: A Promising Therapeutic Target in Cancer. Int J Mol Sci. 2022;23:19.","journal-title":"Int J Mol Sci"},{"key":"720_CR92","doi-asserted-by":"publisher","unstructured":"Rejili M. Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics. Discover Oncol. 2026;17(1):377. https:\/\/doi.org\/10.1007\/s12672-026-04492-5.","DOI":"10.1007\/s12672-026-04492-5"},{"key":"720_CR93","doi-asserted-by":"publisher","unstructured":"Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14):7517. https:\/\/doi.org\/10.3390\/ijms25147517.","DOI":"10.3390\/ijms25147517"},{"issue":"5","key":"720_CR94","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3892\/mco.2024.2776","volume":"21","author":"P Papalexis","year":"2024","unstructured":"Papalexis P, Georgakopoulou VE, Drossos PV, Thymara E, Nonni A, Lazaris AC, et al. Precision medicine in breast cancer (Review). Mol Clin Oncol. 2024;21(5):78.","journal-title":"Mol Clin Oncol"},{"key":"720_CR95","doi-asserted-by":"publisher","unstructured":"Wang Y, Minden A. Current molecular combination therapies used for the treatment of breast cancer. Int J Mol Sci. 2022;23(19):11046. https:\/\/doi.org\/10.3390\/ijms231911046.","DOI":"10.3390\/ijms231911046"},{"key":"720_CR96","first-page":"100268","volume":"14","author":"MA Samad","year":"2025","unstructured":"Samad MA, Ahmad I, Zughaibi TA, Suhail M, Zaidi SK, Al-Abbasi FA, et al. Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions. Eur J Med Chem Rep. 2025;14:100268.","journal-title":"Eur J Med Chem Rep"},{"key":"720_CR97","doi-asserted-by":"publisher","first-page":"175883592413094","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo D, Ascione L, Guidi L, Marsicano RM, Koukoutzeli C, Trapani D, et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Therapeutic Adv Med Oncol. 2025;17:17588359241309461.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"4","key":"720_CR98","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/hemoncstem.HEMONCSTEM-D-24-00042","volume":"18","author":"R Paz-Manrique","year":"2025","unstructured":"Paz-Manrique R, Pinto JA, Gomez Moreno HL. Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action. Hematol Oncol Stem Cell Ther. 2025;18(4):133\u20139.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"720_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/atm-25-34","volume":"13","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia M, Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Annals translational Med. 2025;13(2):18.","journal-title":"Annals translational Med"},{"key":"720_CR100","doi-asserted-by":"publisher","unstructured":"Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. PARP inhibitors for breast cancer: germline BRCA1\/2 and beyond. Cancers. 2022;14(17):4332. https:\/\/doi.org\/10.3390\/cancers14174332.","DOI":"10.3390\/cancers14174332"},{"key":"720_CR101","doi-asserted-by":"publisher","unstructured":"Alharbi S, Qasem FF, Talebi MT, Omran NE, Hamoudi R, Harati R. Immunotherapy approaches for the treatment of triple-negative breast cancer. Cancers. 2026;18(3):464. https:\/\/doi.org\/10.3390\/cancers18030464.","DOI":"10.3390\/cancers18030464"},{"key":"720_CR102","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/IJN.S443692","volume":"19","author":"Y Lv","year":"2024","unstructured":"Lv Y, Li W, Liao W, Jiang H, Liu Y, Cao J, et al. Nano-Drug Delivery Systems Based on Natural Products. Int J Nanomed. 2024;19:541\u201369.","journal-title":"Int J Nanomed"},{"key":"720_CR103","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.rsurfi.2025.100529","volume":"19","author":"S Islam","year":"2025","unstructured":"Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery\u2013A review. Results Surf Interfaces. 2025;19:100529.","journal-title":"Results Surf Interfaces"},{"key":"720_CR104","doi-asserted-by":"publisher","unstructured":"Delou JMA, Souza ASO, Souza LCM, Borges HL. Highlights in resistance mechanism pathways for combination therapy. Cells. 2019;8(9):1013. https:\/\/doi.org\/10.3390\/cells8091013.","DOI":"10.3390\/cells8091013"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00720-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:02:02Z","timestamp":1790647322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00720-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00720-8","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"82"}}